CalciMedica (CALC) chief business officer gets 186,729-share stock award at $0.8033

Rhea-AI Filing Summary

CalciMedica, Inc. director and chief business officer Eric W. Roberts reported a stock award of common shares. He acquired 186,729 shares of common stock at $0.8033 per share in a grant or award transaction. The securities were issued under a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026, which was approved by an independent committee of the board of directors.

Following this grant, Roberts directly holds 366,435 common shares. He also has indirect holdings through several entities and retirement accounts, including 316,109 shares held by Valence Investments SPV VI, LLC, 356,989 shares held by Valence Investments SPV IV, LLC, and additional positions in IRA and Roth IRA accounts.

Insights

Equity compensation analyst

Eric W. Roberts received a sizable stock award in a board-approved purchase agreement.

Eric W. Roberts, a director, chief business officer, and ten-percent owner of CalciMedica, acquired 186,729 common shares at $0.8033 per share via a grant or award. The award stems from a Securities Purchase Agreement dated June 23, 2026, with closing on June 25, 2026.

The agreement and issuance were approved by an independent board committee, indicating formal governance review of the terms. After this transaction, Roberts holds 366,435 shares directly, plus significant indirect positions through Valence entities and retirement accounts, so the grant increases his already substantial exposure to the company.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Roberts Eric W

Role CHIEF BUSINESS OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	186,729	$0.8033	$150K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 366,435 shares (Direct, null); Common Stock — 84,150 shares (Indirect, By FMTC Custodian - Roth IRA FBO Eric W. Roberts)

Footnotes (1)

1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein.

Key Figures

Stock award size: 186,729 shares Award price per share: $0.8033 per share Direct holdings after grant: 366,435 shares +5 more

8 metrics

Stock award size 186,729 shares Common stock grant to Eric W. Roberts

Award price per share $0.8033 per share Transaction price for granted shares

Direct holdings after grant 366,435 shares Eric W. Roberts direct common stock position

Valence SPV VI indirect holdings 316,109 shares Common stock held by Valence Investments SPV VI, LLC

Valence SPV IV indirect holdings 356,989 shares Common stock held by Valence Investments SPV IV, LLC

IRA indirect holdings 10,661 shares Common stock via IRA Financial Trust Company CFBO Eric W. Roberts

Roth IRA indirect holdings (Oppenheimer) 49,894 shares Common stock via Oppenheimer & Co Inc. Custodian Roth IRA

Roth IRA indirect holdings (FMTC) 84,150 shares Common stock via FMTC Custodian - Roth IRA

Key Terms

Securities Purchase Agreement, independent committee, beneficially own, pecuniary interest, +1 more

5 terms

Securities Purchase Agreement financial

"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

independent committee regulatory

"The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board"

An independent committee is a group of individuals within a company who are tasked with reviewing important decisions, such as mergers or acquisitions, without influence from the company's management or major shareholders. Their role is to provide impartial judgment, helping ensure that decisions are made fairly and in the best interest of all stakeholders. For investors, this adds a layer of objectivity and transparency to significant corporate actions.

beneficially own financial

"may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

pecuniary interest financial

"The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein"

ten percent owner regulatory

"is_ten_percent_owner": 1"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 08:45 AM Accepted by SEC EDGAR 06/29/2026 - 08:45 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts Eric W

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST BLVD. S. #307

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF BUSINESS OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		A(1)		186,729	A	$0.8033	366,435	D
Common Stock								84,150	I	By FMTC Custodian - Roth IRA FBO Eric W. Roberts
Common Stock								49,894	I	By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA
Common Stock								10,661	I	By IRA Financial Trust Company CFBO Eric W. Roberts
Common Stock								356,989	I	By Valence Investments SPV IV, LLC(2)
Common Stock								66,228	I	By Valence Investments SPV V, LLC(2)
Common Stock								316,109	I	By Valence Investments SPV VI, LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

2. The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein.

	/s/ John Dunn, Esq., Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Eric W. Roberts report in this CalciMedica (CALC) Form 4 filing?

Eric W. Roberts reported receiving a grant of 186,729 CalciMedica common shares at $0.8033 per share. The shares were issued under a Securities Purchase Agreement with a June 25, 2026 closing, approved by an independent board committee.

Was the CalciMedica (CALC) stock transaction an open-market buy or a grant?

The transaction was a grant or award acquisition, not an open-market purchase. It is coded as transaction type “A” on the Form 4, reflecting shares issued under a Securities Purchase Agreement rather than bought on the open market.

How many CalciMedica (CALC) shares does Eric W. Roberts hold directly after this filing?

After the reported grant, Eric W. Roberts directly holds 366,435 shares of CalciMedica common stock. This figure comes from the Form 4 line showing total shares following the transaction for his direct ownership position.

What price was used for the CalciMedica (CALC) share grant to Eric W. Roberts?

The grant to Eric W. Roberts used a per-share value of $0.8033. This price is listed on the Form 4 as the transaction price per share for the 186,729 common shares acquired in the award transaction.

Did an independent committee approve Eric W. Roberts’ CalciMedica (CALC) stock issuance?

Yes. The footnotes state the Securities Purchase Agreement and the issuance of securities to Eric W. Roberts were approved by an independent committee of CalciMedica’s board of directors, indicating separate oversight of the transaction’s terms.

What indirect CalciMedica (CALC) holdings related to Eric W. Roberts are shown on the Form 4?

The filing lists indirect holdings including 316,109 shares via Valence Investments SPV VI, LLC, 356,989 shares via Valence Investments SPV IV, LLC, and additional shares through IRA and Roth IRA custodians associated with Eric W. Roberts.